HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its second quarter 2021 financial results on August 12, 2021, before market opening. The company focuses on developing novel immunotherapeutics using its proprietary arenavirus platform, with ongoing clinical trials for HPV 16-positive cancers and Cytomegalovirus. HOOKIPA aims to mobilize T cells and antibodies to combat serious diseases, with additional preclinical research in prostate cancer, HIV, and Hepatitis B in collaboration with Gilead Sciences.
- Progress in clinical trials for HPV 16-positive cancers and Cytomegalovirus.
- Collaborations with Gilead Sciences for research in prostate cancer, HIV, and Hepatitis B.
- None.
NEW YORK and VIENNA, Austria, Aug. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release second quarter 2021 financial results and recent highlights before the market opens on Thursday, August 12, 2021.
The Company will not be conducting a conference call in conjunction with this earnings release.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells and antibodies, the body’s natural infection killers, to fight or prevent serious disease.
HOOKIPA is developing a broad pipeline of potential first-in-class arenaviral immunotherapies in oncology and infectious disease. We are leveraging our proprietary, versatile platform to engineer arenaviral therapeutics that induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies to a broad range of self and non-self antigens, including viral antigens, tumor-associated antigens and neoantigens. Our immunotherapies are designed to use either non-replicating or replicating viral vectors based on the target disease, with the potential to induce CD8+ T cell response levels previously not achieved by other immunotherapy approaches.
HOOKIPA’s pipeline include ongoing clinical trials in Human Papilloma Virus 16-positive cancers and Cytomegalovirus, as well as preclinical research in prostate cancer, HIV and Hepatitis B. The latter two are in collaboration with Gilead Sciences, Inc.
Find out more about HOOKIPA online at www.hookipapharma.com.
| For further information, please contact: | |
| Media | Investors |
| Nina Waibel | Matt Beck |
| Senior Director - Communications | Executive Director - Investor Relations |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
FAQ
When will HOOKIPA Pharma release its Q2 2021 financial results?
What is the focus of HOOKIPA Pharma's research?
Is HOOKIPA Pharma conducting any clinical trials?
Who is collaborating with HOOKIPA Pharma in its research?
